Lupus News

A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement system in human tissue, a discovery that could reshape the treatment of many rheumatic and autoimmune diseases.

A risk prediction score that uses machine learning and a patient’s genetic information may identify autoimmune conditions up to 1,000% more accurately than current models, according to findings published in Nature Communications.

Pericarditis recurrence in lupus is more likely — and has a dose-dependent relationship — with oral prednisone treatment, though overall it is lower than in the general population, according to data published in JAMA Network Open.

More than one-third of patients with systemic lupus erythematosus experience a flare after starting dialysis for end-stage renal disease, according to data published in Arthritis Care & Research.

Learning from 2 decades of off-label rituximab use in systemic lupus erythematosus may point the way toward developing “new and improved” B-cell depleting agents for patients with the disease, according to researchers.

Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity and remission, and more time spent in those states, vs. standard therapy alone, according to data.

ORLANDO — Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according to a presenter at the American Academy of Dermatology Annual Meeting.

Although chimeric antigen receptor T-cell therapy has delivered previously unthinkable remission outcomes to patients with lupus and other rheumatic diseases, the cells currently in use remain “old fashioned,” according to a speaker.

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has several limitations that may be overcome instead through bispecific T-cell-engaging antibodies, according to a speaker.